Cullen Capital Management LLC Acquires New Holdings in Zoetis Inc. $ZTS

Cullen Capital Management LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,152 shares of the company’s stock, valued at approximately $801,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System bought a new stake in shares of Zoetis in the first quarter worth $2,542,000. Wealthfront Advisers LLC raised its position in Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares during the last quarter. Deutsche Bank AG lifted its holdings in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after buying an additional 891,921 shares during the period. Pincus Capital Management LP acquired a new position in Zoetis during the 4th quarter worth about $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor grew its position in shares of Zoetis by 21.5% in the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after buying an additional 629,974 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ZTS shares. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley set a $85.00 price objective on Zoetis in a research note on Friday, August 7th. Stifel Nicolaus reduced their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Finally, Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $109.23.

Zoetis Trading Down 0.8%

Shares of ZTS stock opened at $77.13 on Tuesday. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $157.21. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a 50 day simple moving average of $75.70 and a two-hundred day simple moving average of $96.81. The company has a market cap of $31.87 billion, a P/E ratio of 12.71, a PEG ratio of 1.82 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.